References
Cross NCP, Reiter A (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207–1212
Schwaller J, Anastasiadou E, Cain D, Kutok J, Woyiski S, Willimas IR, LaStarza R, Crescendi B, Sternberg DW, Andreason P, Schiavo R, Siena S, Mecucci C, Gilliland GD (2001) H4(D10S170), a gene frequently rearranged in papillary thyroid carcinomas, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukaemia with t(5;10)(q33;q22). Blood 97:3910–3918
Kulkarni S, Heath C, Parker S, Chase A, Iqbal A, Pocock F, Kaeda J, Cwynarski K, Goldman JM, Cross NCP (2000) Fusion of H4/D10S170 to the platelet-derived growth factor receptor β in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 60:3592–3598
Garcia JL, FontdeMora J, Hernandez JM, Queizan JA, Gutierrez NC, Hernandez JM San Miguel JF (2003) imatinib mesylat elicts positive clinical response in atypical chronic myeloid leukaemia involving the platelet-derived growth factor receptor beta. Blood 102:2699–2700
Bastie J-N, Garcia I, Terré C, Cross NCP, Mahon F-X, Castaigne S (2004) Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor β-gene. Haematologica 89:1263–1264
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Drechsler, M., Hildebrandt, B., Kündgen, A. et al. Fusion of H4/D10S170 to PDGFRβ in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol 86, 353–354 (2007). https://doi.org/10.1007/s00277-006-0247-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-006-0247-5